http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-101181227-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a4b1eac93fa8426bfd541c9e14e11860 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02 |
| filingDate | 2007-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_91d17bb472747e55312caa58288d62e6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f0ac33f2c2a1f4cc20859de3c50fbf4f |
| publicationDate | 2008-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-101181227-A |
| titleOfInvention | Solid lipid nanometer particle in-situ gel rubber preparations of biological adherent cyclosporine A and preparation method thereof |
| abstract | The invention pertains to the field of medical technology, which discloses a biological adhesive cyclosporine A solid lipid nanoparticle in situ gel preparation and the preparation method thereof. The preparation includes the treatment effective amount of cyclosporin A, emulsifier, lipid material, charge controlling agent/coating material and so on, and each 1000ml preparation contains: 0.05g to 5.0g of cyclosporin A, 0.0g to 50g of lipid material, 0.5 to 60g of emulsifier, 0.1g to 30g of coating material, 200.0g to 500.0g of gel matrix, and the purified water is added to 1000ml. Positive charge material is firstly coated on the nanoparticle surface and then is prepared into in situ gel preparation. The particle size of the nanoparticle which is prepared by the invention is less than 200nm, the envelope rate is higher, the performance is more than the zeta potential of plus23mv and is increased along with the consumption of charge controlling agent/coating material, and the potential is improved. The preparation of the invention shows better adhesion of the dual-mucosa, which can be used in local drug delivery; as the retention time on the drug delivery part is prolonged, the action time of the drug is long, the bioavailability and the treatment index of the drug can be improved, and the dosage, toxicity and side effects can be reduced. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-115475170-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102274175-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102133192-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102133192-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102106821-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102106821-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110876713-A |
| priorityDate | 2007-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 83.